Oura announced the Ring 5 on May 28, 2026, billing it as the world’s smallest smart ring and pairing two features that have not previously appeared together in a consumer wearable: nighttime blood-pressure pattern tracking during sleep and the ability to import clinical lab results directly into its app. The combination positions the device as a bridge between passive biometric monitoring and traditional blood work, though the blood-pressure capability lacks FDA clearance and the underlying clinical study is still running.
Nighttime blood-pressure signals meet lab data in a single ring
The Ring 5 ships with a feature Oura calls Health Radar’s Blood Pressure Signals, which captures what the company describes as nighttime blood-pressure patterns during sleep. Separately, a new Lab Uploads tool lets users photograph or import blood-test panels so that biomarkers like cholesterol, glucose, and inflammatory markers sit alongside ring-collected data inside the Oura App.
The logic behind bundling these two streams is straightforward. Nighttime blood-pressure behavior can differ sharply from daytime readings, and certain nocturnal patterns are associated with elevated cardiovascular risk. Pairing those patterns with lab biomarkers could, in theory, flag users whose combination of sleep-time vascular signals and blood chemistry warrants a conversation with a doctor. The catch is that the value of that pairing depends on users actually getting lab work done and uploading it, which limits the population-level benefit to people already engaged with preventive care.
Oura is not promising a cuff-style reading or a diagnosis. Instead, the company is surfacing patterns that may correlate with hypertension risk, such as a lack of normal overnight “dipping” in blood pressure. Presented next to LDL cholesterol or fasting glucose, those trends could nudge users toward follow-up testing. But without formal validation, the app’s composite view risks implying more certainty than the underlying science currently supports.
Oura’s clinical study and the FDA’s standing warning
The blood-pressure feature did not appear overnight. Oura disclosed earlier that it had been running an investigational program in Oura Labs focused on blood-pressure profiling, and that work is now formally registered on ClinicalTrials.gov under identifier NCT07267871. The study lists an up to 18 months timeframe and defines its primary outcome as the sensitivity of an Oura classification to identify participant-reported hypertension.
Two details in that registry entry stand out. First, the endpoint relies on participant-reported hypertension rather than gold-standard ambulatory blood-pressure monitoring, which means the study is testing whether the ring can match what users already know about their own diagnosis. Second, the study is still active, so no accuracy metrics or participant outcomes have been published. Oura has not stated that the Ring 5’s blood-pressure signals constitute an FDA-cleared measurement, and the company’s own language frames them as “signals” and “patterns” rather than clinical readings.
That framing matters because the FDA maintains a standing safety communication titled “Do Not Use Unauthorized Devices for Measuring Blood Pressure,” which warns consumers against relying on devices that claim to measure blood pressure without proper authorization. The agency directs users to check the 510(k) database before trusting any device for that purpose. No public record confirms that Oura has submitted or received 510(k) clearance for its blood-pressure feature, and the clinical trial listing at ClinicalTrials.gov does not change that regulatory status.
In practical terms, that leaves the Ring 5’s blood-pressure function in a gray zone: more sophisticated than generic wellness scores, but not yet a recognized medical measurement. Oura can study correlations between its nighttime signals and user-reported hypertension, and it can market those signals as tools for awareness. What it cannot credibly do, absent authorization, is present them as a replacement for validated devices used in clinics and pharmacies.
What the Ring 5’s data gap means for buyers
The distinction between a wellness signal and a medical measurement is not academic. A user who sees a nighttime blood-pressure pattern flagged as elevated might reasonably treat that information as a diagnostic finding, especially if it appears alongside uploaded lab results that show borderline cholesterol or glucose. Oura’s decision to display both streams in one interface raises the stakes for how clearly the app communicates the limits of ring-derived data versus clinician-ordered blood work.
Several questions remain open. Oura has not detailed the data-privacy framework governing imported lab results, including whether those results are stored locally, encrypted in transit, or shared with third parties for research. The company has not disclosed how the app will differentiate between a ring-generated pattern and a lab-confirmed value in its user interface. And the clinical study’s reliance on self-reported hypertension, rather than independent verification, leaves open the question of how well the ring performs for users who do not yet know they have high blood pressure, which is precisely the group that would benefit most from early detection.
For anyone considering the Ring 5 specifically for its blood-pressure capability, the practical first step is to confirm whether the feature carries FDA authorization by checking the agency’s publicly searchable 510(k) database. If no clearance appears, the feature should be treated as an informational wellness tool rather than a substitute for a validated blood-pressure cuff or clinical measurement. Users who do upload lab results should verify how that data is stored, whether it is used to train algorithms, and whether it can be fully deleted on request.
The next development to watch is the completion of the NCT07267871 study and publication of its sensitivity results. Those numbers will determine whether Oura’s nighttime blood-pressure classification meaningfully aligns with known hypertension status and how often the system misses or misflags cases. Until then, the Ring 5 offers an ambitious blend of sleep-derived vascular signals and lab-integration features, but buyers should approach its blood-pressure insights as prompts for medical follow-up, not as answers in themselves.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
